Quarterly report · Q1
4521.TEDINET S100RKL3
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥18.1bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥73.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥18.2bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥3.3bn | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥4.1bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥3.5bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥8.7bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.3bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.5bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.0bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥2.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥167.2bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥166.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥165.1bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥29.3bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥29.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥137.8bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥136.8bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥137.9bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥56.8bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥59.6bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥66.99 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥144.8 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥76.91 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 82.1% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E00935-000Medicinereportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥17.5bn |
| jpcrp040300-q1r_E00935-000Medicinereportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥17.5bn |
| jpcrp040300-q1r_E00935-000Medicinereportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥3.0bn |
| jpcrp040300-q1r_E00935-000Real Estatereportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥605m |
| jpcrp040300-q1r_E00935-000Real Estatereportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥605m |
| jpcrp040300-q1r_E00935-000Real Estatereportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥321m |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥18.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥18.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥3.3bn |
| jpcrp040300-q1r_E00935-000Medicinereportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥17.6bn |
| jpcrp040300-q1r_E00935-000Medicinereportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥17.6bn |
| jpcrp040300-q1r_E00935-000Medicinereportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥3.8bn |
| jpcrp040300-q1r_E00935-000Real Estatereportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥615m |
| jpcrp040300-q1r_E00935-000Real Estatereportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥615m |
| jpcrp040300-q1r_E00935-000Real Estatereportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥295m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥18.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥18.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥4.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 374
| Item | Context | Value | Unit |
|---|---|---|---|
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)科研製薬株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都文京区本駒込２－28－８ | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |